Facebook
Twitter
LinkedIn
ForwardPulse: Rechallenging Clozapine After Clozapine Induced Myocarditis
Rechallenging clozapine after myocarditis is a complex, high-risk decision that requires careful consideration and monitoring. While the available data is limited, it offers valuable insights into potential outcomes and essential precautions. This presentation will increase pharmacist competency with rechallenging clozapine after myocarditis and improve patient outcomes.
Target Audience
Pharmacist
Learning Objectives
1. Define clozapine induced myocarditis and examine its epidemiology, pathophysiology, and associated risk factors
2. Identify current literature on rechallenging clozapine after clozapine induced myocarditis and discuss the pharmacist's role in therapy.
3. Recognize patient-specific factors that indicate when rechallenging clozapine after clozapine induced myocarditis may be appropriate.
Additional Information
| Attachment | Size |
|---|---|
 Disclosure Slides_Zecopoulos.pdf | 278.85 KB |
This presentation will increase pharmacist knowledge on the role of lipid-lowering agents in lipoprotein(a) and introduce emerging targeted treatment options that are currently being studied.
Angeleki Zecopoulos, PharmD
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.